Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: January 31, 2019
Expires: January 30, 2020
30 minutes to complete

Jointly Provided By

Postgraduate Institute for Medicine (PIM), in joint providership with RMEI Medical Education (RMEI).

Target Audience

US-based clinicians, including hematology and hematology/oncology and hematology/oncology nurse practitioners and PAs.

Learning Objectives

After engaging in this educational activity, participants will be able to:

  1. Differentiate efficacy and safety data between current, novel, and future therapies for treating patients with hemophilia A without inhibitors and integrate their use into practice
  2. Incorporate appropriate management of hemophilia A with inhibitors in the treatment paradigm, based on the efficacy and safety, and mechanisms of current, novel, and emerging therapies
  3. Describe the mechanisms of action of emerging and novel targets beyond factor VIII and how these may be integrated into the treatment of hemophilia, based on the pathophysiologic underpinnings of the disease
  4. Employ a strong patient-provider collaborative approach to managing patients with hemophilia A that includes recognition and management of quality of life issues in patients with hemophilia A, and incorporates shared decision-making

Activity Description

This multi-activity CME curriculum is designed to meet your clinical needs in hemophilia A. In this activity, you will hear insights from 3 hemophilia experts on the current management approach to hemophilia A without and with inhibitors, new developments in hemophilia A therapies, and ways to incorporate shared decision-making when treating patients with hemophilia A. In addition, you will have an opportunity to practice through a series of questions and compare yourself to your peers.

Statement of Educational Need

An estimated 60% of patients with hemophilia A have the severe form of the disease, which often leads to recurrent bleeding episodes into the joints.1 Recurring joint bleeds can result in debilitating joint disease and chronic pain, which negatively impacts the quality of life of patients living with hemophilia and contributes to significant disability. Patients who have hemophilia A with inhibitors represent an area of unmet need, since they suffer from worse outcomes because their disease is more resistant to prophylaxis and treatments. Hematology providers are challenged to manage hemophilia A and are even more challenged to manage hemophilia A with inhibitors. They also need to remain current with new developments in the field that could dramatically improve patients’ outcomes. While adherence, outcomes, and satisfaction are improved in patients who are engaged and participate in their healthcare decisions, hematology providers may not actively engage in shared decision-making with their patients.

1. Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22(5 Suppl):s126-133.


Steven W. Pipe, MD
Professor, Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, MI

Steven W. Pipe, MD, is a professor and the Laurence A. Boxer research professor of pediatrics and communicable diseases, as well as a professor of pathology at the University of Michigan, Ann Arbor, MI. Dr Pipe completed his undergraduate medical training and received his medical degree from the University of Toronto, Ontario, Canada. He completed his pediatric training at the McMaster University in Hamilton, Ontario, and his pediatric hematology and oncology training and fellowship in the Pediatric Scientist Development Program at the University of Michigan. Dr Pipe is certified by the American Board of Pediatrics in pediatric hematology/oncology.

Dr Pipe is the medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory at the University of Michigan. His clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies. Dr Pipe also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A.

Dr Pipe was awarded a Young Investigator Award from both the American Society of Pediatric Hematology and Oncology and the International Society on Thrombosis and Haemostasis, and a Faculty Scholar Award from the American Society of Hematology. He has been the recipient of the Leadership in Research Award from the National Hemophilia Foundation. Dr Pipe has served on the Board of Directors for the Hemostasis and Thrombosis Research Society, as chair of the Board of Directors for the American Thrombosis and Hemostasis Network, and is currently the Chair of the Medical and Scientific Advisory Committee to the National Hemophilia Foundation.

Steven W. Pipe, MD, has affiliations with Alnylam, Bayer, Biomarin, Bioverativ, Catalyst Biosciences, CSL Behring, DNArx, HEMA Biologics, Novo Nordisk, Pfizer, Roche/Genentech, Shire, Spark Therapeutics, uniQure (Consulting Fees); Shire, Siemens (Contracted Research).

Rebecca Kruse-Jarres, MD, MPH
Medical Director, Bloodworks Northwest
Washington Center for Bleeding Disorders
Seattle, WA

Rebecca Kruse-Jarres, MD, MPH, is the director of the Washington Center for Bleeding Disorders (WACBD) at Bloodworks Northwest in Seattle, WA. She earned her medical degree at Tulane University in New Orleans, LA where she also received a master’s degree in public health and tropical medicine. She completed her residency in internal medicine and fellowship in hematology/oncology at Tulane, became faculty in the Department of Medicine, and served as the associate director of the Louisiana Center for Bleeding and Clotting Disorders. Dr Kruse-Jarres holds faculty appointments in both medicine and pediatrics at the University of Washington and cares for ~900 individuals with inherited bleeding disorders across the state of Washington. She is board-certified in internal medicine, medical oncology, and hematology.

Dr Kruse-Jarres is nationally and internationally known for her work with inhibitors in acquired and congenital hemophilia and has been actively involved with several national and international clinical trials studying new treatments for this patient population. Dr Kruse-Jarres is the president of the Hemostasis and Thrombosis Research Society. She has received many honors and awards, including Best Doctors in America, Louisiana’s Top Doctors, and the Greater New Orleans (GNO) Health and Service Corps Award.

Rebecca Kruse-Jarres, MD, MPH, has affiliations with Grifols, Roche, Shire (Consulting Fees); Roche, Shire (Speakers’ Bureaus).

Cindy A. Leissinger, MD
Professor of Medicine, Clinical Professor of Pathology and Pediatrics
Director, Louisiana Center for Bleeding and Clotting Disorders
Chief, Section of Hematology/Oncology
Tulane University School of Medicine
New Orleans, LA

Cindy A. Leissinger, MD, is currently a professor of medicine and a clinical professor of pediatrics and pathology at Tulane University in New Orleans, LA. She serves as the chief of the Hematology/Oncology Section and is also the director of the Louisiana Center for Bleeding and Clotting Disorders. Dr Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at the National Institutes of Health in Bethesda, MD, and a clinical fellowship in hematology and medical oncology at Tulane. Dr. Leissinger is board-certified in internal medicine and hematology.

Dr Leissinger is actively involved in the American Society of Hematology, the International Society on Thrombosis and Haemostasis, and the Hemostasis and Thrombosis Research Society. In addition to caring for patients with bleeding and clotting disorders, Dr Leissinger oversees an active research program. She participates in several clinical research groups and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in factor VIII inhibitor development and management.

Dr Leissinger has many peer-reviewed publications in numerous journals including Blood, The New England Journal of Medicine, Haemophilia, and Thrombosis Research.

Cindy A. Leissinger, MD, has affiliations with Bayer, CSL Behring, Genentech, HemaBiologics, Kedrion, NovoNordisk, Pfizer, Shire (Advisory Boards); BioMarin, Genentech (Contracted Research).

Conflict of Interest Policy/Disclosure Statement

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email

Complete the evaluation form and participants will be entered into a drawing to win a $100 Amazon Gift Card!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.